AC Immune & Lilly Team Up Again to Stop Alzheimer’s with Brain-Targeting Drugs
AC Immune updates Eli Lilly deal to develop pill-based Tau drugs for Alzheimer’s, aiming to stop disease early with promising preclinical results.
/ 195 items
#XY Event-Driven Stocks↓
Organogenesis’ PuraPly AM Shows Strong Success in Diabetic Foot Ulcer Trial
Organogenesis Holdings says PuraPly AM helps diabetic foot ulcers heal faster than standard care alone in a clinical trial.
Insurer Stocks Soar After CMS Finalizes 2027 Medicare Payments
CMS boosts 2027 Medicare payments 2.5%, giving insurers $13B+, keeping plans stable and seniors’ benefits solid. Stocks jump.
ImmunityBio Quickly Fixes FDA Ad Concerns: Podcast Pulled, TV Spot Never Aired
ImmunityBio addressed FDA ad concerns, removed a podcast, and clarified ANKTIVA info while tightening rules on future promotions.
Vericel Secures Up to $197M BARDA Contract for NexoBrid – 10-Year Deal to Bolster U.S. Burn and Blast Injury Preparedness
Vericel won a 10-year, $197M BARDA deal to supply NexoBrid, a burn treatment, and expand its use and production in the U.S.
FDA Fast Track Boosts Context Therapeutics’ CTIM-76 for Hard-to-Treat Ovarian Cancer
Context Therapeutics’ CTIM-76 wins FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1a trial ongoing with interim data expected in June 2026.